quotes and stock data delayed 15 minutes
Burn Rate (Qtr)
XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.
Click on drug name or indication to see upcoming trial info, prior data, and more general information
Drug | Disease (links)
Stage (next event)
See what the community is saying - click to see full post